Vince & Associates Clinical Research, an Altasciences company, announced today the opening of a controlled ventilation indoor smoking facility offering a human laboratory model of smoking behavior at their clinical research unit in Overland Park, KS.
This smoking facility is divided into two areas with independent ventilation systems to allow for the evaluation of smoking cessation, smoking, vaping, tobacco risk assessment and nicotine delivery. This facility is a part of Vince & Associates’ new four-story building, which is scheduled to fully open in March 2016. The indoor smoking areas allow for the controlled evaluation of pharmaceutical and tobacco products.
“Our experience with both the pharmaceutical and tobacco industries, coupled with our innovative facilities and expert staff, ensure that Vince & Associates is uniquely qualified to conduct these specialized clinical trials,” said Dr. Brad Vince, CEO and Medical Director at Vince & Associates.
The new smoking facility allows for a full range of smoking assessments including those for the human laboratory model of smoking behavior. A dedicated team works with sponsors throughout all stages of their program, from study design and study conduct, to bioanalysis and clinical study report writing.
Altasciences Clinical Research encompasses Algorithme Pharma in Montreal, QC, Vince & Associates Clinical Research in Overland Park, KS, as well as Algorithme Pharma USA in Fargo, ND, thereby making it one of the largest early phase clinical CROs in North America. Altasciences provides early phase clinical development services to an international customer base of biopharmaceutical and generic companies.